|
Researcher | Diagnostic criteria | Sample size | Intervention | Follow-up period | Outcome |
Experiment | Control | Experiment | Control |
|
Jianwei Gao | Guideline for diagnosis and treatment of patients with chronic stable angina, ACC/AHA/ACP–ASIM guidelines for the management of chronic stable Angina + positive result of coronary angiography or CTA or MPI+ | 115 | 117 | Xinling Wan pill | Placebo | 4 weeks | Reduced the amount of nitroglycerin, relieved symptoms |
Junbo Ge | After AMI or PCI or CABG, epicardial coronary stenosis of ≥50% in at least one major branch | 1335 | 1327 | Shexiang Baoxin pill + optimal medical therapy | Placebo + optimal medical therapy | 24 months | Reduced the occurrence of MACEs, reduced angina frequency |
Ming Guo | After PCI | 530 | 524 | Xinyue capsule + standard treatment | Placebo + standard treatment | 1 year | Reduced occurrence of primary endpoint event |
Zhijie Shen | Guidelines for the diagnosis and treatment of unstable angina pectoris and non-ST-segment Elevation myocardial infarction + guidelines for the diagnosis and treatment of acute ST-elevation myocardial infarction | 92 | 95 | Suxiao Jiuxin pill + standard treatment | Placebo + standard treatment | 12 months | Reduced the occurrence of MACEs, improved LVEF and SAQ |
Wang Yonggang | After PCI + TCM syndrome differentiation | 67 | 62 | Shuangshen Tongguan capsule + standard treatment | Placebo + standard treatment | 6 months | Improved LVEF and SAQ, increased k-value of the microcirculation perfusion |
Danping Xu | ACC/AHA guidelines for the management of patients with chronic stable angina + TCM syndrome differentiation | 59 | 55 | Shenzhu Guanxin recipe + standard treatment | Placebo + standard treatment | 90 days | Improved SAQ and daily exercise tolerance, reduced the amount of nitroglycerin |
Jingen Li | Patients with SCAD | 750 | 750 | Qing-Xin-Jie-Yu Granule + standard treatment | Placebo + standard treatment | 12 months | Reduced risk of the composite “hard” endpoint |
Mei Zhang | Patients with noncalcified plaque | 607 | 605 | Tongxinluo capsule + standard treatment | Placebo + standard treatment | 24 months | Reduced IMT and major cardiovascular events |
Narayanaswamy Venketasubramanian | Ischemic stroke of intermediate severity (NIHSS) in the preceding 72h, neuroimaging findings compatible with cerebral infarction and mRS ≤1. | 550 | 549 | NeuroAiD (Danqi Piantan capsule) + standard treatment | Placebo + standard treatment | 24 months | No obvious difference in rates of death and occurrence of vascular and other medical events |
Darioush Savadi Oskouei | AIS involving anterior cerebral circulation | 52 | 50 | Ginkgo biloba | Placebo | 4 months | Reduced NIHSS score |
|